bioRxiv Science⌕ Search

Biology subjects

Prata, L. L.

Publications and source records attributed to Prata, L. L..

2 recordsLinked to original sources

Syndecan-1 Promotes Alveolar Type 2 Epithelial Cell Senescence during Lung Fibrosis.

Idiopathic pulmonary fibrosis (IPF) is an age-related, progressive, and fatal interstitial lung disease for which effective therapies remain limited. Alveolar type 2 (AT2) epithelial cells serve as facultative stem cells essential for alveolar repair; however, AT2 cell senescence disrupts epithelial regeneration and contributes to fibrotic remodeling in IPF. Syndecan-1 is a transmembrane heparan sulfate proteoglycan predominantly expressed by lung epithelial cells, but its role in AT2 dysfunction during fibrosis is poorly defined. Here, we demonstrate that syndecan-1 is robustly upregulated in AT2 cells in IPF and other fibrotic lung diseases, as well as in murine bleomycin-induced lung fibrosis. Syndecan-1 expression was further enhanced with aging and associated with increased fibrotic burden in aged mice. Using integrated human transcriptomic analyses, mouse genetic models, and epithelial cell-based systems, we show that excess syndecan-1 promotes cell-autonomous epithelial senescence and impairs AT2 progenitor function. Elevated syndecan-1 reduced AT2 renewal capacity, disrupted differentiation, and diminished surfactant protein C level, whereas genetic loss of syndecan-1 attenuated senescence and preserved epithelial function following injury. Together, these findings identify syndecan-1 as a critical epithelial regulator of AT2 senescence and maladaptive repair in pulmonary fibrosis and support targeting syndecan-1-driven epithelial dysfunction as a potential therapeutic strategy.

cell biology↗

The natural flavonoid dihydromyricetin targets senescent cells via PRDX2 and alleviates age-related diseases

Aging is a preeminent risk factor for chronic diseases, with cellular senescence as one of the major hallmarks and an effective target to delay, prevent or alleviate age-related disorders. Here we report in vitro screening outputs from a natural medicinal agent (NMA) library, wherein dihydromyricetin (DMY), a natural flavonoid, showed senotherapeutic potential. DMY protected senescent fibroblasts from further DNA damage and attenuated the senescence-associated secretory phenotype (SASP), acting as a senomorphic agent. Proteomics suggested that DMY promotes nuclear translocation of peroxiredoxin 2 (PRDX2), a reactive oxygen species (ROS) scavenger, facilitating DNA repair in senescent cells. In prematurely aged mice, DMY administration mitigated tissue aging changes and age-related physiological decline. In anticancer regimens, DMY improved outcomes of chemotherapy. However, DMY demonstrated senolytic activity against senescent microglial cells, wherein basal PRDX2 expression remains low, by impairing mitochondrial function to promote ROS-mediated apoptosis. In mice developing an Alzheimers disease (AD)-like state, DMY eliminated senescent microglial cells from amyloid {beta}-protein (A{beta}) plaques, alleviating A{beta}-associated pathological phenotypes. Together, our study proposes DMY to be a natural senotherapeutic agent representing a therapeutic solution for mitigating age-related morbidities including but not limited to cancers and AD.

cell biology↗